Dicerna Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on June 30, 2015, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 115,500 shares of common stock to four new employees, with all four grants having a grant date of June 30, 2015 (the "Q2 2015 Inducement Grants").

Help employers find you! Check out all the jobs and post your resume.